NV-TOMTOM
TomTom (TOM2 ) is announcing the launch of the new TomTom Sports app today, bringing not just activity data, but insights and motivation, to millions of users.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170105005171/en/
The new TomTom Sports app, co-created with athletes and fitness app users, gets people going by introducing motivational messages, activity trends and comparisons, performance stats down to the second, rich social sharing functions, presented in an attractive and friendly design.
“We have been creating wearables since 2009, and since then much has changed. The large amounts of data people now have access to, is overwhelming. What people really need in that moment where excuses beat conviction, is motivation and a better understanding of what works for them. With our new TomTom Sports app we turn data into insights to do just that. This launch marks the beginning of what will be a hugely exciting year for our brand in the world of sports.” Says Corinne Vigreux, Co-Founder and Managing Director TomTom Consumer.
The TomTom Sports app provides a single place to track up to 12 different activity types ranging from running, cycling and swimming to skiing, trail running and hiking.
The app can show your latest efforts and achievements – such as changes in body composition1 and resting heart rate1 - at a glance. It also enables more advanced athletes to examine performance analytics on a by-the-second level. With smart comparisons users can now benchmark their latest performance against their personal bests.
The new TomTom Sports app enables seamless data sharing with a range of third party platforms like Strava, Nike+, Endomondo, MapMyFitness, Runkeeper and many more.
Coming to your smartphone soon
The new TomTom Sports app will be available for download from the Apple Store and Google Play2 store starting at the end of January in most countries. The app works with iOS4 and Android3 smartphones and supports the TomTom Runner, TomTom Touch, TomTom Adventurer, TomTom Spark and TomTom Multi-Sport wearable ranges. For more information go to tomtom.com/sportsapp or watch our TomTom Sports App Product Video: https://youtu.be/KoJ5tyJsi7o
Visitors to CES can visit TomTom to find out more at: Sands Expo Hall C, Booth #43705 (level 2).
ENDS
The TomTom Sports app is compatible with the following devices:
Android: To ensure an excellent mobile experience, make sure to use the TomTom Sports App on phones with Bluetooth Smart (4.1 or higher) and Android version 4.4 or higher. The app needs to be connected to the internet to exchange information with your TomTom device. The following Android phones are supported:
• Samsung S7, S7 Edge, S6, S6 Edge, S5, S5 Mini, S5 Plus, S4, S4 Mini, A3, A5, Note 3, Note 4, J5
• Nexus 5, 5X, 6
• HTC One M8, M9
• LG G3, G4
• Sony Xperia Z3, Z3 Compact, Z5, Z5 Compact
• Huawei P8, P8 Lite
• OnePlus One
We will continue to add new phones to the list of supported Android devices in the future.
iOS: The TomTom Sports App only works on iPhone4 4S or higher and iOS8 or higher. The app needs to be connected to the internet to exchange information with your TomTom device.
About TomTom Sports
TomTom Sports is on a mission to help you get going.
Since 2009, we’ve developed Sports and Fitness products that make it easier to get moving.
We were the first to add an optical heart-rate monitor to a GPS Sports Watch with the TomTom Runner Cardio , and by integrating a music player into our Sports Watches we have enabled you to leave your smartphone at home. We’ve always been focused on innovating to make it easier to get going.
We also recently launched TomTom Touch , the first fitness tracker that combines body composition analysis with steps, sleep and all day heart-rate tracking, right from the wrist, technology usually reserved for elite athletes.
Find the full TomTom Sports product lineup here .
About TomTom
At TomTom (TOM2) our mission is to make technology so easy to use, that everyone can achieve more.
We created easy to use navigation devices, helping millions of people to get where they want to be. Today, we continue to simplify the complex, making technology more accessible for everyone.
We serve four different markets: Consumer, Telematics, Automotive and Licensing.
We make easy to use navigation devices, sport watches and action cameras for consumers. We enable businesses with vehicles to more easily manage and improve fleet efficiency whilst increasing overall business performance with our Telematics solutions. We also offer a world leading real-time map platform that is powering innovative location based services and helping to make automated driving a reality for the automotive industry.
Founded in 1991 and headquartered in Amsterdam, we have over 4,600 employees and sell our products worldwide.
1 Only with supporting TomTom devices
2 Google Play is a trademark of Google Inc.
3 Android is a trademark of Google Inc.4 iOS and iPhone are trademarks of Apple Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170105005171/en/
Contact:
For More Information:
Media
Rosanne van
Poelvoorde
+31 20 75 74 056
rosanne.vanpoelvoorde@tomtom.com
or
Investor
Relations
Bisera Grubesic
+31 20 75 75 194
ir@tomtom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom